Poolbeg Pharma
Poolbeg Pharma is a clinical-stage biopharmaceutical company developing POLB 001, an oral p38 MAPK inhibitor for cancer immunotherapy-induced cytokine release syndrome and severe influenza, alongside an oral GLP-1 obesity therapy, with a licensing-oriented business model targeting large pharmaceutical partners.
- Company typePublic
- Founded2021
- HeadquartersDublin, Ireland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Poolbeg Pharma does
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company listed on the London Stock Exchange's AIM market (ticker: POLB) and dual-headquartered in London and Dublin. Founded in July 2021 as a spin-out from hVIVO plc (formerly Open Orphan plc), the company develops small-molecule and oral biologics targeting infectious disease, cancer immunotherapy side effects, and metabolic disease. Its lead asset, POLB 001, is an oral p38 MAP kinase inhibitor being developed in two indications: prevention of cytokine release syndrome (CRS) in cancer immunotherapy patients and treatment of severe influenza. POLB 001 received FDA Orphan Drug Designation in May 2025 and is currently in a Phase IIa TOPICAL trial (activated June 2026, interim data expected summer 2026) across six NHS sites, with Johnson & Johnson providing its bispecific antibody teclistamab as part of the RISE research programme. A second programme applies AnaBio Technologies' pH-sensitive microencapsulation platform to develop an oral GLP-1 receptor agonist for obesity, currently in preclinical proof-of-concept at the University of Ulster.
The company's business model is asset-light and licensing-oriented. As a clinical-stage developer with no commercial products, Poolbeg intends to monetize its pipeline through licensing or partnership deals with large pharmaceutical companies following proof-of-concept clinical data, rather than building its own commercialization infrastructure. It pursues cost-efficient clinical trials designed to produce high-quality human data that accelerate partnering discussions. The company supplements its internal pipeline with AI-led drug discovery programmes for influenza (with CytoReason) and RSV (with OneThree Biotech), leveraging its inherited repository of 20+ years of human challenge trial data as a competitive differentiator. Poolbeg holds a global patent estate covering POLB 001 across the US, Europe, Japan, Australia, and Canada, with potential protection extending to 2044 in oncology indications.
The company serves three primary constituencies: (1) large pharmaceutical companies developing cancer immunotherapies and metabolic disease therapeutics, who are the intended licensing counterparties; (2) cancer treatment centers and hospitals that would administer POLB 001 alongside bispecific antibodies and CAR T-cell therapies to enable safer, outpatient administration; and (3) patients with multiple myeloma, DLBCL, severe influenza, or obesity who stand to benefit from the company's pipeline candidates. Poolbeg is debt-free with a £10m cash balance and runway into 2027, supported by an oversubscribed £4.1m equity raise completed in June 2025.
Poolbeg Pharma firmographics
Firmographics- Name
- Poolbeg Pharma
- Legal name
- Poolbeg Pharma Plc
- Website
- https://poolbegpharma.com
- Company type
- Public
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Poolbeg Pharma is a clinical-stage biopharmaceutical company developing POLB 001, an oral p38 MAPK inhibitor for cancer immunotherapy-induced cytokine release syndrome and severe influenza, alongside an oral GLP-1 obesity therapy, with a licensing-oriented business model targeting large pharmaceutical partners.
- Ownership category
- akta.pro rank
Poolbeg Pharma industry classification
Industry- Product category
- Clinical-stage biopharmaceutical drug development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
- akta.pro secondary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Poolbeg Pharma is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Offices2 records
Markets served
Poolbeg Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Licensing and Partnership Deals: Poolbeg Pharma's primary revenue strategy is to partner with large pharmaceutical companies for licensing deals after generating proof-of-concept clinical data. The company aims to maximize value through significant transactions with pharma partners.
- Future Product Sales: Pre-revenue clinical stage company. Potential future revenue from product sales if any drug candidates receive regulatory approval and are commercialized.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels9 records
Poolbeg Pharma product offering
Product offeringCore offering
Poolbeg Pharma is a clinical-stage biopharmaceutical company developing drug candidates for infectious diseases, cancer immunotherapy complications, and metabolic disease. Its lead asset, POLB 001, is an oral p38 MAP kinase inhibitor being developed to prevent cytokine release syndrome (CRS) in cancer immunotherapy patients and for severe influenza. The company is also advancing an oral encapsulated GLP-1 therapy for obesity and operating AI-led drug discovery programmes for influenza and RSV leveraging proprietary human challenge trial data.
Product overview
Poolbeg Pharma is a clinical-stage biopharmaceutical company with a portfolio of drug development programmes. The core products include POLB 001 (an oral p38 MAPK inhibitor) being developed for two indications: cancer immunotherapy-induced CRS (cytokine release syndrome prevention) and severe influenza treatment. The company is also developing an Oral Encapsulated GLP-1 therapy for obesity using proprietary microencapsulation technology. Additionally, Poolbeg operates AI-led drug discovery programmes for influenza and RSV, leveraging unique human challenge trial data combined with AI合作伙伴 (CytoReason and OneThree Biotech) to identify novel drug targets and candidates.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- TNF-α reduction of 73.5% and 56.2% for 70mg and 150mg doses respectively in LPS challenge trial
- +5 more outcomes
Companies that use Poolbeg Pharma
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Poolbeg Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Poolbeg Pharma partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Johnson & JohnsoncoreJ&J providing its bispecific antibody for use in Poolbeg's TOPICAL trial within the RISE research programme. The RISE programme focuses on understanding and managing CRS related to cancer immunotherapies. Collaboration aims to facilitate safer administration of immunotherapies by researching CRS prevention methods.
- AnaBio TechnologiescoreCollaboration with AnaBio Technologies for oral vaccine programme using proprietary encapsulation technology. Irish Government's Disruptive Technologies Innovation Fund awarded €2.3m non-dilutive grant to the consortium. Validating encapsulation process to develop Phase I clinical trial-ready oral vaccine candidate. Technology also being applied to oral GLP-1 programme.
- CytoReasoncorePartnership with leading AI company CytoReason to analyze Poolbeg's unique influenza disease progression data. Harnesses insights from Poolbeg's repository of influenza human challenge trial data together with CytoReason's curated disease data and validated AI technology. Successfully identified multiple novel drug targets for influenza.
- OneThree BiotechcorePartnership with biology-driven AI company OneThree Biotech to identify new treatments for RSV. Poolbeg's scientific team worked closely with OneThree to build tailored AI approach leveraging unique RSV human challenge trial data. Successfully identified disease-relevant pathways and drug candidates, with positive outputs from lab-based analysis.
- University of WarwickminorLicensed RNA-based immunotherapy for respiratory viruses from University of Warwick. Acquired immunotherapy candidate for further development.
- Accelerating Clinical Trials (ACT)coreACT appointed to conduct Phase IIa TOPICAL trial of POLB 001. Specialist blood cancer trials organization running the trial across multiple NHS sites.
- The Christie NHS Foundation TrustcoreOne of six NHS hospital sites conducting the TOPICAL trial. The Christie is a specialist cancer center and Chief Investigator site.
- The Royal MarsdencoreNHS hospital site participating in TOPICAL trial for POLB 001.
- University College London HospitalscoreNHS hospital site participating in TOPICAL trial for POLB 001.
- University Hospitals BirminghamcoreNHS hospital site participating in TOPICAL trial for POLB 001.
- NHS Lothian (Edinburgh)coreNHS hospital site in Scotland participating in TOPICAL trial for POLB 001.
- Royal Stoke University HospitalcoreNHS hospital site participating in TOPICAL trial for POLB 001.
- University of UlstercoreUniversity of Ulster conducting proof of concept trial for oral encapsulated GLP-1 programme. Prof Carel le Roux serves as trial investigator.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Poolbeg Pharma competitors and assessment
Company assessmentEmerging players
- Evelo Biosciences: Clinical-stage inflammation/immunology biotech working on immune-mediated diseases, including oncology supportive care adjacencies. Comparable small-cap clinical-stage profile.
- Recursion Pharmaceuticals: AI-driven drug discovery company. Poolbeg's AI programmes with CytoReason and OneThree Biotech follow a similar computational biology/drug discovery paradigm, although at earlier stage and narrower scope.
Direct peers
- AnaptysBio Inc: Clinical-stage immunology company developing antibodies for inflammatory and immunologically-mediated diseases, including cytokine release considerations. Comparable clinical-stage development model and inflammation focus.
- Inflazome Ltd: Direct historical peer in p38 MAPK/NLRP3 inhibitor development, acquired by Roche for $450M+ in 2020. CEO Jeremy Skillington was previously VP BD at Inflazome, making this the most comparable corporate trajectory for Poolbeg.
- hVIVO plc: Poolbeg's former parent (spun out in 2021). Operates human challenge trial services for respiratory viruses including influenza and RSV — directly linked to Poolbeg's data assets and the source of its human challenge trial data moat.
- Valneva SE: European clinical-stage biopharma developing vaccines and therapeutics for infectious diseases. Comparable size, AIM/Euronext listing, and similar infectious disease focus including influenza programmes.
- Scancell Holdings plc: UK AIM-listed clinical-stage immunology biotech developing cancer immunotherapies and infectious disease vaccines. Similar size, listing venue, and pipeline mix of immunology and infectious disease programmes.
Regional players
- Benevolent AI: UK/EU-based AI drug discovery company applying machine learning to identify novel therapeutic targets. Comparable in applying AI to pharmaceutical R&D, though focused on different disease areas.
- Oncimmune Holdings plc: UK AIM-listed clinical-stage company with a similar small-cap profile. Adjacent in oncology/immunology focus, useful as a regional market comparable for AIM-listed clinical-stage UK biotechs.
Others
- CytoReason: AI partner of Poolbeg for the influenza programme. Adjacent technology provider whose disease-models platform is integrated into Poolbeg's AI drug discovery workflow.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Poolbeg Pharma social profiles
Digital presencePoolbeg Pharma compliance and trust
Trust signalCompliance1 record
Poolbeg Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Poolbeg Pharma leadership team
Management profileNumber of profiles
Profiles6 records
Poolbeg Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Poolbeg Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Poolbeg Pharma
What does Poolbeg Pharma do?
Poolbeg Pharma is a clinical-stage biopharmaceutical company developing drug candidates for infectious diseases, cancer immunotherapy complications, and metabolic disease. Its lead asset, POLB 001, is an oral p38 MAP kinase inhibitor being developed to prevent cytokine release syndrome (CRS) in cancer immunotherapy patients and for severe influenza. The company is also advancing an oral encapsulated GLP-1 therapy for obesity and operating AI-led drug discovery programmes for influenza and RSV leveraging proprietary human challenge trial data.
Is Poolbeg Pharma a public or private company?
Poolbeg Pharma is a public company. It is classified as public and is currently operating.
When was Poolbeg Pharma founded?
Poolbeg Pharma was founded in 2021. It employs 11 to 50 people.
Where is Poolbeg Pharma based?
Poolbeg Pharma is headquartered in Dublin, Ireland, in the Europe region.
How does Poolbeg Pharma make money?
Two revenue lines are on record. Licensing and Partnership Deals are the primary driver. The others are future Product Sales.
Who are Poolbeg Pharma's main competitors?
Emerging players on record are Evelo Biosciences and Recursion Pharmaceuticals. Direct peers are AnaptysBio Inc, Inflazome Ltd, hVIVO plc, Valneva SE and Scancell Holdings plc. Regional players are Benevolent AI and Oncimmune Holdings plc. CytoReason is listed as an others.
Does Poolbeg Pharma have an API?
No public API is recorded for Poolbeg Pharma.
What industry is Poolbeg Pharma in?
Poolbeg Pharma's product category is Clinical-stage biopharmaceutical drug development. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2836.